Corporate StrategyNovo Nordisk Outsources Parkinson's R&D to AI Partner as Big Pharma Drops Vertical IntegrationSalvado•Jun 9, 2026
Corporate StrategyNovo Nordisk Licenses Cell Therapy to AI Spinout as Big Pharma Rewrites Its R&D PlaybookSalvado•Jun 1, 2026
Pharma StrategyNovo Nordisk's 24.9% Rally Validates AI Licensing Over Internal Cell TherapySalvado•May 31, 2026
Corporate StrategyNovo Nordisk Closes Internal Cell Therapy Unit, Licenses Program to AI-Native Cellular IntelligenceSalvado•May 21, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingSalvado•May 18, 2026
Pharma FinanceNovo Nordisk Licenses Parkinson's Program and Exits Cell Therapy as AI Reshapes Pharma R&DSalvado•May 16, 2026
Pharma & HealthcareNovo Nordisk's 24.9% Stock Surge Validates Pharma's Pivot From Internal R&D to AI PartnershipsSalvado•May 13, 2026
